After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
GE to set up its FlexFactory platform for antibody manufacturing at Akeso’s facility in Guangzhou, aiming to optimize the latter’s biologics production.
The high growth rate in the uptake of biologics in emerging markets represents a major opportunity for those companies developing biosimilars, suggests one pharma exec.
BioLife announces acquisition of Custom Biogenic Solutions, with the company’s latest deal adding liquid nitrogen laboratory freezers and cryogenic equipment to its portfolio.
Regardless of the quality of the raw materials used in bioproduction processes, variability is a very common threat that can be addressed, says Thermo Fisher executive.
Solid Biosciences announces that its gene therapy for DMD has been placed under clinical hold again, after a patient experienced a serious adverse event.
